CONTROLLED RELEASE COMPOSITIONS COMPRISING ANTI-CHOLINERGIC DRUGS

• US 20110311626A1
• Filed: 02/23/2010
• Published: 12/22/2011
• Est. Priority Date: 02/23/2009
• Status: Abandoned Application

• Current Assignee: Adare Pharmaceuticals, Inc.
• Original Assignee: Adare Pharmaceuticals, Inc.
• Inventors: Venkatesh, Gopi, Gatti, Paolo, Parrino, Vincent, Fabiani, Flavio
• Application Number:
  US13/202,957
• Publication Number:
  US 20110311626A1
• Time in Patent Office: Days
• US Class Current: 424/468
• CPC Class Codes: A61K 9/0056 Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• CPC Class Codes: A61K 9/1676 having a drug-free core with discrete complete coating layer containing drug adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K9/141; with further drug-free outer coating A61K9/5078; drug conjugated to non-active particles A61K47/6921
• CPC Class Codes: A61K 9/2081 with microcapsules or coated microparticles according to A61K9/50
• CPC Class Codes: A61K 9/5042 Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/5047 Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/5078 with drug-free core
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/08 for nausea, cinetosis or vertigo; Antiemetics
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 11/08 Bronchodilators
• CPC Class Codes: A61P 21/02 Muscle relaxants, e.g. for tetanus or cramps
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system

Abstract

The present invention provides compositions comprising dicyclomine, or salts, and/or solvates and methods of making and using the compositions to treat intestinal hypermotility or Irritable Bowel Syndrome (IBS). The present invention also provides once-a-day orally disintegrating dosage forms comprising compositions of the present invention.

Claims

1. A controlled release composition comprising a plurality of anti-cholinergic drug-containing particles, the particles comprising:

(a) a core comprising an anti-cholinergic drug;

(b) a first coating disposed over the core comprising at least one water-insoluble polymer; and

(c) a second coating disposed over the core comprising an enteric polymer optionally in combination with a water-insoluble polymer.

2. The controlled release composition of claim 1, wherein the second coating comprises a water-insoluble polymer in combination with an enteric polymer.

3. The controlled release composition of claim 1, wherein the second coating is disposed over the first coating.

4. The controlled release composition of claim 3, wherein the first coating comprises the combination of a water-insoluble polymer and an enteric polymer, and the second coating comprises an enteric polymer.

5. The controlled release composition of claim 2, wherein the second coating is disposed over the first coating.

6. The composition of claim 2, wherein the ratio of the water-insoluble polymer to the enteric polymer is about 10:

1 to about 1;

1.

7. The controlled release composition of claim 1, wherein at least one of the first and second coatings further comprise a plasticizer.

8. The controlled release composition of claim 5, wherein at least one of said first and second coatings further comprise a plasticizer.

9. The controlled release composition of claim 8, wherein the first and second coatings further comprise a plasticizer.

10. The controlled release composition of claim 1, wherein the core comprises an anti-cholinergic drug coated onto an inert core.

11. The controlled release composition of claim 9, wherein the core comprises an anti-cholinergic drug coated onto an inert core.

12. The composition of claim 1, wherein the core further comprises a polymeric binder selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone and mixtures thereof.

13. The composition of claim 1 further comprising:

(d) a plurality of rapidly-dispersing microgranules each having an average particle size of not more than about 400 μ

m and comprising (i) a disintegrant and (ii) a sugar alcohol and/or a saccharide, wherein said sugar alcohol and/or saccharide each have an average particle size of not more than about 30 μ

m.

14. The composition of claim 13, wherein the ratio of rapidly-dispersing microgranules to anti-cholinergic drug-containing particles ranges from about 6:

1 to about 1;

2.

15. The composition of claim 13, wherein the rapidly-dispersing microgranules comprise a disintegrant selected from the group consisting of crosslinked polyvinylpyrrolidone, sodium starch glycolate, crosslinked carboxymethylcellulose of sodium, low-substituted hydroxypropylcellulose and mixtures thereof.

16. The composition of claim 2, wherein the second coating comprises about 5 to about 60 wt % relative to the total weight of the anti-cholinergic drug-containing particle.

17. The composition of claim 1, wherein the anti-cholinergic drug is selected from the group consisting of atropine, benactyzine, benztropine, biperiden, butylscopolammonium bromide, cyclopentolate darifenacin, dexetimide, dicyclomine, emepronium, glycopyrrolate, hexahydrosiladifenidol, octylonium, orphenadrine, oxybutynin, oxyphenonium, pirenzepine, procyclidine, propantheline propylbenzilylcholine, quinidine, scopolamine, tolterodine trihexyphenidyl, tropicamide, mivacurium, atracurium, doxacurium, cisatracurium, vecoronium, rocuronium, pancuronium, tabocurarine, gallamine, pipecuronium, hexamethonium, mecamylamine, trimethaphan, succinylcholine, suxamethonium, decamethonium, methoxycoronaridine, mecamylamine, imidafenacin, and pharmaceutically acceptable salts, hydrates, polymorphs, and/or solvates thereof.

18. The composition of claim 1, wherein the anti-cholinergic drug is dicyclomine or salts, polymorphs, and/or solvates thereof

19. The composition of claim 9, wherein the anti-cholinergic drug is dicyclomine or salts and/or hydrates thereof

20. The composition according to claim 1, wherein the water-insoluble polymer is selected from the group consisting of ethylcellulose, cellulose acetate, cellulose acetate butyrate, polyvinyl acetate, neutral methacrylic acid/methylmethacrylate copolymers, and mixtures thereof.

21. The composition of claim 1, wherein the enteric polymer is selected from the group consisting of cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, pH-sensitive methacrylic acid/methylmethacrylate copolymers, shellac, and mixtures thereof

22. The composition of claim 1, wherein the water-insoluble polymer is ethylcellulose and the enteric polymer is hydroxypropylmethylcellulose phthalate.

23. The composition of claim 19, wherein the water-insoluble polymer is ethylcellulose and the enteric polymer is hydroxypropylmethylcellulose phthalate.

24. The composition of claim 1, wherein the anti-cholinergic drug-containing particles exhibit a drug release profile substantially corresponding to the following pattern when dissolution tested using United States Pharmacopoeia Apparatus 2 (paddles @ 50 rpm) in a 2-stage dissolution media (700 mL of 0.1N HCl for the first 2 hrs followed by testing in 900 mL buffer at pH 6.8 obtained by adding 200 mL of a pH modifier) at 37°

C.;

after 4 hours, about 40±

20% of the total anti-cholinergic drug is released;

after 8 hours, about 65±

25% of the total anti-cholinergic drug is released; and

after 12 hours, about 70±

30% of the total anti-cholinergic drug is released.

25. A dosage form comprising the controlled release composition of claim 1.

26. A dosage form comprising the controlled release composition of claim 19.

27. The dosage form of claim 26, further comprising:

(d) a plurality of rapidly-dispersing microgranules each having an average particle size of not more than about 400 μ

m and comprising (i) a disintegrant and (ii) a sugar alcohol and/or a saccharide, wherein said sugar alcohol and/or saccharide each have an average particle size of not more than about 30 μ

m;

wherein said dosage forth is an orally disintegrating tablet.

28. The dosage form of claim 27, wherein said orally disintegrating tablet substantially disintegrates within about 60 seconds after contact with saliva in the oral cavity or simulated saliva fluid.

29. The dosage form of claim 27, wherein said orally disintegrating tablet substantially disintegrates within about 30 seconds when disintegration is tested according to the USP <

701>

Disintegration Test.

30. A method of preparing a controlled release composition of claim 1, comprising:

(a) preparing a plurality of cores comprising an anti-cholinergic drug;

(b) coating said cores with said first coating; and

(c) coating said cores with said second coating.

31. The method of claim 30, wherein said coating of step (b) is carried out prior to said coating of step (c).

32. The method of claim 30, further comprising:

(d) granulating a sugar alcohol and/or a saccharide, each having an average particle diameter of not more than about 30 μ

m, and a disintegrant, thereby producing rapidly disintegrating microgranules with an average particle size not more than about 400 μ

m;

(e) blending the coated core particles and rapidly disintegrating microgranules;

(f) compressing said blend of coated core particles and rapidly disintegrating microgranules, thereby forming an orally disintegrating tablet.

33. The method of claim 30, wherein the anti-cholinergic drug is selected from the group consisting of atropine, benactyzine, benztropine, biperiden, butylscopolammonium bromide, cyclopentolate darifenacin, dexetimide, dicyclomine, emepronium, glycopyrrolate, hexahydrosiladifenidol, octylonium, orphenadrine, oxybutynin, oxyphenonium, pirenzepine, procyclidine, propantheline propylbenzilylcholine, quinidine, quinuclidinyl benzilate, scopolamine, tolterodine trihexyphenidyl, tropicamide, mivacurium, atracurium, doxacurium, cisatracurium, vecoronium, rocuronium, pancuronium, tabocurarine, gallamine, pipecuronium, hexamethonium, mecamylamine, trimethaphan, succinylcholine, suxamethonium, decamethonium, methoxycoronaridine, mecamylamine, and imidafenacin.

34. The method of claim 33, wherein said anti-cholinergic drug comprises dicyclomine or a salt, polymorph, and/or hydrate thereof

35. The method of claim 32, wherein said orally disintegrating tablet substantially disintegrates within about 60 seconds after contact with saliva in the oral cavity or simulated saliva fluid.

36. The method of claim 32, wherein said orally disintegrating tablet substantially disintegrates within about 30 seconds after contact with saliva in the oral cavity or simulated saliva fluid.

37. A method of treating intestinal hypermotility or irritable bowel syndrome, comprising administering a therapeutic amount of the composition of claim 1 to a patient in need thereof

38. A method of treating intestinal hypermotility or irritable bowel syndrome, comprising administering a therapeutic amount of the dosage form of claim 27 to a patient in need thereof.

39. A method of increasing compliance in a patient suffering from intestinal hypermotility or irritable bowel syndrome, comprising administering a therapeutic amount of the dosage form of claim 27 to a patient in need thereof.

40. A controlled release composition comprising a plurality of drug-containing particles, the particles comprising:

(a) a core comprising a drug;

(b) a first coating disposed over the core comprising at least one water-insoluble polymer; and

(c) a second coating disposed over the core comprising an enteric polymer optionally in combination with a water-insoluble polymer

(d) wherein the drug has a short plasma elimination half-life and requires frequent dosing to minimize adverse events.

41. A controlled release composition a plurality of drug-containing particles, the particles comprising:

(a) a core comprising the drug;

(b) a first coating disposed over the core comprising a water-insoluble polymer; and

(c) a second coating disposed over the first coating comprising an enteric polymer.

42. The controlled release composition of claim 41, wherein the drug is selected from the group consisting of analgesics anticonvulsants, antidiabetic agents, anti-infective agents, anti-Parkinsonian agents, antirheumatic agents, cardiovascular agents, central nervous system (CNS) stimulants, dopamine receptor agonists, anti-emetics, gastrointestinal agents, psychotherapeutic agents, opioid agonists, opioid antagonists, anti-epileptic drugs, histamine H₂ antagonists, anti-asthmatic agents, and skeletal muscle relaxants.